Back

Short and medium-term safety and tolerability of Sacubitril-Valsartan and Empaglifozin joint intake

26 May 2019 (08:30 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 2 - Chronic Heart Failure – Treatment Pharmacotherapy HFA Premium Access Heart Failure 2019

About the speaker

Photo
Doctor Herminio Morillas Climent

University Hospital Bellvitge, Barcelona (Spain)

55 More presentations in this session

Presentation thumbnail
Doctor A. Ntalianis (Athens, GR)
Abstract
Presentation thumbnail
Doctor J. AGOSTINHO (Lisbon, PT)
Abstract
Presentation thumbnail
Doctor F. Ferreira (Cascais, PT)
Abstract
Presentation thumbnail
Ms E. O'Donoghue (Dublin, IE)
Abstract
Presentation thumbnail
Doctor V. Gomez Leiva (San Salvador, SV)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 2 - Chronic Heart Failure – Treatment

The Event

Event poster

Heart Failure 2019

26 May 2019 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Safety and tolerability of sacubitril/valsartan in chronic heart failure and reduced ejection fraction: results from the open-label extension of PARADIGM-HF
21 May 2023
thumbnail
Congress Presentation
Comparison of sodium-glucose cotransporter-2 (SGLT2) inhibitors to reduce cardiovascular and renal outcomes: a network meta-analysis of randomized controlled trials
28 August 2023
thumbnail
Congress Presentation
Divergent electrophysiologic safety profile of dapagliflozin and empagliflozin in a whole-heart model
27 August 2022
thumbnail
Congress Presentation
Safety and efficacy of initiation SGLT in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease on top of standard therapy with ARNI or ACE-i
31 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources